Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most indications and several dosing/tablet-strength and administration details are supported by the provided label excerpts. However, multiple key safety statements are inaccurate or unsupported by the excerpts (notably kidney-problem “common side effects” and claims about monitoring/age-related lower dosing and specific side-effect claims), and pediatric dosing details are partly inaccurate.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin medication used to lower cholesterol levels.
Label excerpt includes mechanism (12.1) describing inhibition of HMG-CoA reductase and cholesterol/triglycerides reduction; hyperlipidemia indications (1.2).
Lipitor is available in 10 mg, 20 mg, 40 mg, and 80 mg tablet strengths.
Section 3 (DOSAGE FORMS AND STRENGTHS): 10, 20, 40, and 80 mg tablets.
For adults, the recommended starting dose of Lipitor is 10 mg to 20 mg once daily.
Section 2.1: recommended starting dose is 10 or 20 mg once daily.
The maximum recommended dose of Lipitor is 80 mg once daily.
Section 2.1: dosage range is 10 to 80 mg once daily.
Lipitor can be administered as a single dose at any time of the day, with or without food.
Section 2.1: single dose at any time of day, with or without food.
Regular monitoring of Lipitor efficacy and safety is crucial to ensure optimal treatment outcomes.
Section 2.1: after initiation/titration, lipid levels should be analyzed within 2 to 4 weeks and dosage adjusted; Section 5.2: liver function tests prior to and at 12 weeks after initiation and after dose elevations.
Common side effects of Lipitor may include muscle pain or weakness.
Section 6.1 includes myalgia as a discontinuation adverse reaction (0.7%).
Common side effects of Lipitor may include diarrhea.
Section 6.1 includes diarrhea as a discontinuation adverse reaction (0.5%) and as commonly reported regardless of causality (6.8%).
Common side effects of Lipitor may include nausea.
Section 6.1 includes nausea as a discontinuation adverse reaction (0.4%).
Patients should not stop taking Lipitor without consulting their healthcare provider.
Label excerpt provided does not directly state this. However, label does state drug should be temporarily withheld or discontinued in certain conditions (5.1) and that treatment includes continuation with monitoring; direct support not available in provided excerpts.
Unsupported Statements
Lipitor is used to prevent cardiovascular disease.
Supported in part by label indications for prevention of cardiovascular outcomes in specified adult populations (1.1), but the claim is presented broadly without specifying the label’s population/criteria. Not fully supported as written.
Patients with higher risk of cardiovascular disease may require higher doses of Lipitor.
Label excerpt supports individualized starting/maintenance dosing based on patient characteristics and goal/response (2.1) but does not explicitly tie 'higher risk of cardiovascular disease' to 'require higher doses.'
Patients with established cardiovascular disease or diabetes may benefit from higher doses of atorvastatin (Lipitor).
Label excerpt supports indicated risk reduction in these populations (1.1) but does not state that higher doses are beneficial specifically for 'established cardiovascular disease or diabetes' as a dosing recommendation.
Lipitor is not recommended for children under 10 years old.
Label excerpt states it has not been studied in controlled trials in patients younger than 10 years (8.4), but provided excerpts do not state 'not recommended.'
For adolescents aged 10 to 17 years, the recommended dose of Lipitor is 10 mg to 20 mg once daily.
Label excerpt (2.2) states recommended starting dose is 10 mg/day and maximum is 20 mg/day; it does not expressly state a '10 mg to 20 mg' recommended dose range.
Older adults may require lower dosages of Lipitor due to age-related changes in kidney function.
Provided excerpts do not discuss age-related dosing adjustments or kidney-function-based dose reduction. Section 2.5 says renal disease does not affect concentrations and dosage adjustment is not necessary.
Older adults may experience increased risk of muscle damage and kidney problems with higher doses of atorvastatin (Lipitor).
Label excerpt (5.1) links rhabdomyolysis with acute renal failure secondary to myoglobinuria, but the provided excerpts do not provide an age-specific statement nor claim that older adults have increased risk with higher doses.
Common side effects of Lipitor may include liver damage.
Label excerpts list hepatic enzyme increase and biochemical liver function abnormalities and provide monitoring guidance, but do not support 'liver damage' as a common side effect phrasing in the provided adverse reaction excerpt.
Common side effects of Lipitor may include kidney problems.
Provided adverse reaction excerpt (6.1) does not list kidney problems as a common adverse reaction. Although rhabdomyolysis with acute renal failure is mentioned in warnings (5.1), the claim is framed as a common side effect.
Patients should not stop taking Lipitor without consulting their healthcare provider.
No such patient instruction is present in the provided label excerpts.
Contradictions
Low
AI Statement
Common side effects of Lipitor may include kidney problems.
Label Reference
Section 6.1 (Clinical trial adverse experiences) provided does not list kidney problems as a common adverse reaction; Section 5.1 mentions rare rhabdomyolysis with acute renal failure, not a common side effect.
Important Omissions
Pregnancy and nursing contraindications (and associated discontinuation guidance) were not addressed by the AI claims list, though they are material safety information in the label.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several safety-related statements are either unsupported or overly general (e.g., 'kidney problems' and 'liver damage' as common side effects). Some dosing and pediatric/age claims are also not supported as written, which could mislead risk/monitoring expectations.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple statements (especially adverse reaction frequency/organ specificity and age/pediatric dosing recommendations) are not supported by the provided FDA label excerpts or are stated more broadly than the label language.
Suggested Improvement
Constrain claims to label-supported wording: specify that kidney issues are described in the context of rare rhabdomyolysis with acute renal failure (warnings) rather than common side effects; replace 'not recommended' in <10 years with 'not studied'; describe pediatric dosing as starting 10 mg/day with maximum 20 mg/day; avoid age-related dose-lowering claims because label excerpt says renal dysfunction does not require dose adjustment.